Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.
about
Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine.Noninvasive Imaging of CCR2+ Cells in Ischemia-Reperfusion Injury After Lung Transplantation.64Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model.89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide.Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab).Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast CancerEvaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts
P2860
Q39389369-D1E6A414-4A81-4ACF-A9FC-71E3F6C4F0B0Q41631567-595B4A99-7F3C-4D58-B9EB-8F8FF7B3FEF5Q42756624-047E9C16-E23D-4601-AD4F-3BC5BF8EA6DBQ43992554-43D8D350-DF84-482D-8F54-F5FA58C7AE55Q48184539-2CEECD9F-DBD9-4FF9-809A-98655C339223Q50876579-F8EE4FA3-334E-4D6F-A079-E1F2E494B59EQ55384914-ADD685BB-DA70-4C1B-B3F0-7AF7C6880D5BQ57110662-7962F25F-76EE-4C6E-99DD-25F9F0964A0BQ57116004-790BCADF-1A69-4D4E-90B7-96F94EF2EB61
P2860
Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase 1 Evaluation of [(64)Cu] ...... ts with Advanced Solid Tumors.
@ast
Phase 1 Evaluation of [(64)Cu] ...... ts with Advanced Solid Tumors.
@en
type
label
Phase 1 Evaluation of [(64)Cu] ...... ts with Advanced Solid Tumors.
@ast
Phase 1 Evaluation of [(64)Cu] ...... ts with Advanced Solid Tumors.
@en
prefLabel
Phase 1 Evaluation of [(64)Cu] ...... ts with Advanced Solid Tumors.
@ast
Phase 1 Evaluation of [(64)Cu] ...... ts with Advanced Solid Tumors.
@en
P2093
P2860
P1476
Phase 1 Evaluation of [(64)Cu] ...... ts with Advanced Solid Tumors.
@en
P2093
A Craig Lockhart
Barry A Siegel
Farrokh Dehdashti
Jeanne Mendell
Jennifer Frye
Joel Picus
Lauren Trull
Madhuri Desai
Michael J Welch
Richard Laforest
P2860
P2888
P304
P356
10.1007/S11307-015-0912-Y
P577
2015-11-13T00:00:00Z